Genotoxicity studies of ubidecarenone (coenzyme Q10) manufactured by bacteria fermentation.
Ubidecarenone (coenzyme Q10) has been widely used as a complementary therapy in heart failure and as a dietary supplement for over two decades. Ubidecarenone is manufactured by organic synthesis, yeast (non-Saccharomyces cerevisiae) fermentation, or bacteria fermentation. There are many reports on the safety of ubidecarenone. However, genotoxicity of ubidecarenone manufactured by bacteria fermentation has not been reported. We carried out genotoxicity evaluation of ubidecarenone manufactured by bacteria fermentation through the bacterial reverse mutation test (Ames test) and in vitro chromosome aberration test in compliance with the Japanese guidelines on genotoxicity testing of pharmaceuticals and the Organization for Economic Co-operation and Development (OECD) guidelines for testing chemicals. The results indicate neither increase of revertant colonies nor chromosome aberration, suggesting that the ubidecarenone manufactured by bacteria fermentation has no genotoxic activities under the condition of this study.
Yamaguchi
Noriko
N
Bozo Research Center Inc., Tokyo 151-0065, Japan.
Nakamura
Kaori
K
Oguma
Yoshihiro
Y
Fujiwara
Sho
S
Takabe
Michihito
M
Sono
Akira
A
Kawasaki
Tsuneshirou
T
Otsubo
Kazumasa
K
Wakigawa
Koichi
K
D000818:Animals; D001419:Bacteria / Q000378:metabolism; D002460:Cell Line; D006224:Cricetinae; D003412:Cricetulus; D004305:Dose-Response Relationship, Drug; D005260:Female; D005285:Fermentation; D008297:Male; D009152:Mutagenicity Tests / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000096:biosynthesis / Q000633:toxicity
D014451:Ubiquinone; C024989:coenzyme Q10